The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | Updates on the use of nivolumab in Hodgkin lymphoma & how this agent may impact treatment
In this video, Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, comments on the important role of nivolumab in the treatment of Hodgkin lymphoma (HL), highlighting the promising results obtained with the use of this agent, and further discusses the value of investigating other anti-PD1 antibodies in this space. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Research funding: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Advisory boards: Takeda
Speakers’ bureau: BeiGene, MSD
